%0 Journal Article
%A Marques, Joana
%A Valle-Delgado, Juan José
%A Urbán, Patricia
%A Baró, Elisabet
%A Prohens, Rafel
%A Mayor, Alfredo
%A Cisteró, Pau
%A Delves, Michael
%A Sinden, Robert E
%A Grandfils, Christian
%A de Paz, José L
%A García-Salcedo, José A
%A Fernàndez-Busquets, Xavier
%T Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery
%D 2017
%@ 1549-9634
%U http://hdl.handle.net/10668/2612
%X The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.
%K Glycosaminoglycans
%K Malaria
%K Nanomedicine
%K Plasmodium
%K Targeted drug delivery
%K Quitosano
%K Recuento de eritrocitos
%K Antimaláricos
%K Insectos vectores
%K Heparina
%~